All Celgene articles
-
BusinessBristol-Myers Squibb to buy Celgene for $74 billion
Deal boosts BMS’s cancer and immunology pipeline with 5 drugs in late stage clinical trials
-
BusinessCelgene takes a punt on M&A
Cancer specialist bags Juno therapeutics and Impact Biomedicines
-
BusinessUS to invest $160m in cancer partnership
Funds will be backed up with $55m from 11 companies to advance new cancer treatments that harness the immune system
-
BusinessCelgene pays $280m to settle off-label marketing lawsuit
Whistleblower case relating to cancer prescriptions
-
BusinessCelgene and BeiGene agree cancer partnership
Immuno-oncology deal sees firms exchange licensing rights for antibody drugs
-
BusinessCelgene and Jounce team up against cancer
Firms promise next-generation immuno-oncology as existing drugs rack up successes
-
-
Business
Celgene to buy immune-inflammatory specialist Receptos
$7.2bn deal further strengthens Celgene’s position in immunology
-
Business
Celgene backs immunotherapy with Juno collaboration
$1bn investment in 10-year CAR-T cell partnership for cancer treatments
-
Business
Clinical collaborations drive cancer immunotherapy
Companies race to pair up chemotherapy drugs with immune system-boosting antibodies to greatest effect in trials